Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Cardiotoxicity × empagliflozin × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Cardiotoxicity 1

Interventions

Doxorubicin 5 Dexrazoxane 5 Vincristine 4 Razoxane 4 Etoposide 3 Radiotherapy 2 Prednisone 2 Methotrexate 2 Granulocyte Colony-Stimulating Factor 2 Filgrastim 2 Cyclophosphamide 2 Carvedilol 2 Bleomycin 2 schizandrin 1 pegfilgrastim 1 hydrocortisone hemisuccinate 1 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination 1 empagliflozin 1 Watchful Waiting 1 VAP-cyclo protocol 1 Rituximab 1 Ramipril 1 Prednisolone 1 Observation 1 Nebivolol 1 Mercaptopurine 1 Leucovorin 1 Lenalidomide 1 Ivabradine 1 Ifosfamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05271162 2025-11-21

EMPACT

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 3 Recruiting

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡